About: Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias
Creator	Alfandari, S Georges, H Leroy, O Turbelin, C Boussekey, N Chiche, A Delannoy, P.-Y Devos, P Meybeck, A
Source	PMC
abstract	Pharmacodynamic studies report on the rapid bactericidal activity of aminoglycosides, conferring them as being of theoretical interest for bacteraemia treatment. We assessed this issue in a retrospective study of patients with intensive care unit (ICU)-acquired bacteraemias. To determine the impact of aminoglycosides in antimicrobial combination on the outcome of patients with bacteraemia, we performed a monovariate analysis and a logistic regression analysis comparing patients treated with or without aminoglycosides. Forty-eight bacteraemias in 48 patients were included. Eighteen patients received aminoglycosides. Baseline characteristics as well as adaptation and adequation of antibiotherapy did not differ in patients who did or did not receive aminoglycosides. Patients who received aminoglycosides had longer time alive away from the ICU (11.3 ± 8.9 (10 [0–20]) vs. 3.2 ± 6.6 (0 [0–2] days; p = 0.002) and free from mechanical ventilation (12.5 ± 9.3 (14 [0–21] vs. 5.5 ± 9.2 (0 [0–10] days; p = 0.02) on day 28. The ICU mortality was 16% in the aminoglycoside group versus 46% (p = 0.03). In the multivariate analysis, patients treated with aminoglycosides were 6 times less likely to die than those treated without aminoglycosides (confidence interval [CI] = [1.3–28.9]; p = 0.02). Our study supports the hypothesis that combination short-term antibiotherapy with an aminoglycoside for ICU-acquired bacteraemias could increase survival.
has issue date	2012-02-15(xsd:dateTime)
bibo:doi	10.1007/s10096-012-1568-z
bibo:pmid	22350387
has license	no-cc
sha1sum (hex)	efeb50a86739d925306dc8532fe42b48c8be93e5
schema:url	https://doi.org/10.1007/s10096-012-1568-z
resource representing a document's title	Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias
has PubMed Central identifier	PMC7102278
has PubMed identifier	22350387
schema:publication	Eur J Clin Microbiol Infect Dis
resource representing a document's body	covid:efeb50a86739d925306dc8532fe42b48c8be93e5#body_text
is schema:about of	named entity 'treated' named entity 'LIKELY' named entity 'DIE' named entity 'HYPOTHESIS' named entity 'AMINOGLYCOSIDE' named entity 'MECHANICAL VENTILATION' named entity 'IMPACT' named entity 'BASELINE CHARACTERISTICS' named entity 'TREATED WITH' named entity 'ISSUE' named entity 'DAYS' named entity 'OUTCOME' named entity 'FORTY-EIGHT' named entity 'comparing' named entity 'aminoglycosides' named entity 'patients' named entity 'days' named entity 'studies' named entity 'aminoglycosides' named entity 'aminoglycosides' named entity 'group' named entity 'combination' named entity 'regression analysis' named entity 'aminoglycoside' named entity 'aminoglycosides' named entity 'intensive care unit' named entity 'aminoglycosides' named entity 'aminoglycosides' named entity 'aminoglycosides' named entity 'combination therapy' named entity 'linezolid' named entity 'kidney function' named entity 'intensive care units' named entity 'meningitis' named entity 'evolution' named entity 'endocarditis' named entity 'bacteraemia' named entity 'bacteraemia' named entity 'meta-analysis' named entity 'ICU' named entity 'bacteraemia' named entity 'ICU' named entity 'bacteraemia' named entity 'drug-resistant' named entity 'AGs' named entity 'Catheter' named entity 'SAS software' named entity 'radiotherapy' named entity 'blood culture' named entity 'adverse events' named entity 'SOFA score' named entity 'antimicrobial agents' named entity 'microorganisms' named entity 'monotherapy' named entity 'antimicrobial agents' named entity 'End-stage kidney disease' named entity 'serum creatinine' named entity 'combination therapy' named entity 'bacteraemia' named entity 'nosocomial infection' named entity 'risk of death' named entity 'Enterobacteriaceae' named entity 'chronic renal failure' named entity 'genitourinary tract' named entity 'ICU' named entity 'bacteraemia' named entity 'mechanical ventilation' named entity 'Hospital-acquired' named entity 'ICU' named entity 'infection' named entity 'C-reactive protein' named entity 'beta-lactam' named entity 'antibiogram'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software